GH Research (FRA:1KA) Current Accrued Expense: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1KA GH Research PLC FRA:1KA
33 GF Score
Price €23.60
! 2 Warning Signs
View Full Analysis

What is GH Research Current Accrued Expense?

GH Research FRA:1KA -0.84% 33 Current Accrued Expense is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:1KA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

GH Research's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0.00 Mil.

GH Research's quarterly Current Accrued Expense declined from Dec. 2025 (€2.85 Mil) to Mar. 2026 (€0.00 Mil) but then stayed the same from Mar. 2026 (€0.00 Mil) to Jun. 2026 (€0.00 Mil).

GH Research's annual Current Accrued Expense increased from Dec. 2023 (€2.13 Mil) to Dec. 2024 (€3.69 Mil) but then declined from Dec. 2024 (€3.69 Mil) to Dec. 2025 (€2.85 Mil).

GH Research Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for GH Research's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GH Research Current Accrued Expense Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 1.50 2.23 2.13 3.69 2.85

GH Research Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 2.85 0.00 0.00
FRA:1KA
33GF Score
GH Research PLC FRA:1KA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GH Research Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.00 Mil mean?
GH Research (FRA:1KA) has a Current Accrued Expense of €0.00 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on GH Research and its competitors.
Is GH Research's Current Accrued Expense too high?
GH Research's current Current Accrued Expense is €0.00 Mil. Overall, GH Research has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GH Research's Current Accrued Expense compare to XNCR and TSHA?
GH Research's Current Accrued Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on GH Research and its competitors. GH Research's current Current Accrued Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GH Research stock overvalued right now?
GH Research (FRA:1KA) has a current Current Accrued Expense of €0.00 Mil. The current Current Accrued Expense is €0.00 Mil. GH Research's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For GH Research (FRA:1KA), the current Current Accrued Expense is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GH Research Business Description

Other Exchanges GHRS:USA
Address Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
33GF Score

Get the complete analysis for FRA:1KA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.60
Price